GlassScriptPhysician profile
Suma Chennubhotla
NPI 1235420621
$6,307.37
in general payments reported to CMS, 2019-2025
37 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $229 · 2021: $269 · 2022: $1,380 · 2023: $1,503 · 2024: $1,210 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.77 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.97 | 2020-2025 | Viberzi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,068.77 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $716.53 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Qol Medical, LLC | $608.61 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $498.10 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $296.98 | 2022-2025 | |
| Pfizer INC. | $228.23 | 2019-2025 | |
| Lilly USA, LLC | $200.29 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $108.89 | 2022-2025 | Injectafer |
| Madrigal Pharmaceuticals | $104.36 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $100.14 | 2022-2025 | Dupixent |
| Celgene Corporation | $94.90 | 2019-2024 | Zeposia |
| Braintree Laboratories, INC. | $82.72 | 2022-2025 | Suflave, Sutab |
| Ardelyx, INC. | $80.68 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $80.09 | 2024-2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.53 | 2020-2023 | Amjevita |
| Neuraxis, INC. | $77.03 | 2025 | |
| Ironwood Pharmaceuticals, INC | $69.37 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $64.38 | 2023-2024 | Rebyota |
| Digestive Care, INC. | $57.02 | 2023-2024 | Pertzye |
| Gilead Sciences, INC. | $45.48 | 2025 | |
| Medtronic, INC. | $44.87 | 2021-2025 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.06 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $31.86 | 2023-2025 | Ocaliva |
| Radius Health, INC. | $26.69 | 2019-2021 | |
| Celltrion USA INC. | $25.02 | 2024 | Vegzelma |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
| Axonics, INC. | $18.45 | 2023 | Axonics |
| Alnylam Pharmaceuticals INC. | $17.59 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.35 | 2025 | Iqirvo |
| Shield Therapeutics INC | $16.31 | 2025 | |
| Micro-Tech Endoscopy USA, INC. | $15.23 | 2022 | |
| Merck Sharp & Dohme LLC | $14.32 | 2024 | Dificid |
| Organon LLC | $13.98 | 2023 | Hadlima, Renflexis |
| Shionogi INC | $11.89 | 2019 | |
| Redhill Biopharma INC. | $11.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suma Chennubhotla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.